VTAMA®(Tapinarof)乳霜*治疗银屑病。

Q4 Medicine

Skinmed Pub Date : 2022-08-31 eCollection Date: 2022-01-01

Aditya K Gupta, Shruthi Polla Ravi, Kimberly Vincent, William Abramovits

{"title":"VTAMA®(Tapinarof)乳霜*治疗银屑病。","authors":"Aditya K Gupta, Shruthi Polla Ravi, Kimberly Vincent, William Abramovits","doi":"","DOIUrl":null,"url":null,"abstract":"VTAMA® (Tapinarof) 1% cream is a newly approved topical agent for treating plaque psoriasis. The active ingredient, tapinarof, binds to and activates aryl hydrocarbon receptors that positively regulate immune response and skin homeostasis. Tapinarof has presented promising results in two identical phase 3 randomized, double-blind, vehicle-controlled trials, where the primary efficacy end points were observed in 35.4% and 40.2% of patients in the tapinarof group compared to 6.0% and 6.3% of patients in the vehicle group. Tapinarof was applied once daily to affected psoriasis lesions for 12 weeks. Adverse events associated with tapinarof application were folliculitis, contact dermatitis, and headache. (SKINmed. 2022;20:298-300).","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":" ","pages":"298-300"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"VTAMA® (Tapinarof) Cream* for Plaque Psoriasis.\",\"authors\":\"Aditya K Gupta, Shruthi Polla Ravi, Kimberly Vincent, William Abramovits\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"VTAMA® (Tapinarof) 1% cream is a newly approved topical agent for treating plaque psoriasis. The active ingredient, tapinarof, binds to and activates aryl hydrocarbon receptors that positively regulate immune response and skin homeostasis. Tapinarof has presented promising results in two identical phase 3 randomized, double-blind, vehicle-controlled trials, where the primary efficacy end points were observed in 35.4% and 40.2% of patients in the tapinarof group compared to 6.0% and 6.3% of patients in the vehicle group. Tapinarof was applied once daily to affected psoriasis lesions for 12 weeks. Adverse events associated with tapinarof application were folliculitis, contact dermatitis, and headache. (SKINmed. 2022;20:298-300).\",\"PeriodicalId\":21891,\"journal\":{\"name\":\"Skinmed\",\"volume\":\" \",\"pages\":\"298-300\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skinmed\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skinmed","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

VTAMA®(Tapinarof) 1%乳膏是一种新批准的治疗斑块型银屑病的局部用药。活性成分tapinarof结合并激活芳烃受体，积极调节免疫反应和皮肤稳态。Tapinarof在两项相同的3期随机、双盲、载药对照试验中显示出令人满意的结果，Tapinarof组的主要疗效终点分别为35.4%和40.2%，而载药组的主要疗效终点分别为6.0%和6.3%。Tapinarof每天一次应用于受影响的牛皮癣病变，持续12周。与tapinarof应用相关的不良事件有毛囊炎、接触性皮炎和头痛。(SKINmed。20:298 2022; 300)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

VTAMA^® (Tapinarof) Cream* for Plaque Psoriasis.

VTAMA^® (Tapinarof) 1% cream is a newly approved topical agent for treating plaque psoriasis. The active ingredient, tapinarof, binds to and activates aryl hydrocarbon receptors that positively regulate immune response and skin homeostasis. Tapinarof has presented promising results in two identical phase 3 randomized, double-blind, vehicle-controlled trials, where the primary efficacy end points were observed in 35.4% and 40.2% of patients in the tapinarof group compared to 6.0% and 6.3% of patients in the vehicle group. Tapinarof was applied once daily to affected psoriasis lesions for 12 weeks. Adverse events associated with tapinarof application were folliculitis, contact dermatitis, and headache. (SKINmed. 2022;20:298-300).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Skinmed Medicine-Medicine (all)

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： SKINmed is a peer-reviewed bimonthly publication circulated to more than 28,000 dermatologists, allergists, internists, pediatricians, and family practitioners with an interest in dermatology and allergy. SKINmed features articles, original papers, and case studies concerning clinical aspects of dermatology, including dermatopathology, diagnostics, occupational dermatology, malignancy/tumors, cosmetic dermatology, endocrine diseases, infestations, infections, and pharmacotherapy.